" class="no-js "lang="en-US"> GO2 Foundation - Medtech Alert
Thursday, August 07, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
GO2 Foundation | Pharmtech Focus

GO2 Foundation

About GO2 Foundation

GO2 Foundation

The Bonnie J. Addario Lung Cancer Foundation and Lung Cancer Alliance have teamed up to put lung cancer patients and survivors first! GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

Related Story

Diseases

 US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer | Pharmtech Focus

US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer

October 18 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]